Moderna stock rises by over 90% due to the expected success of phase III trials for mRNA cancer vaccine
2026-08-19 20:47:08
According to CoinMeta, Moderna stock rose by over 90% in pre-market trading due to the success of the first phase three clinical trials of its mRNA cancer vaccine.
Bullish 0
Bearish 0
Source:Crypto Briefing
This content is for market information only and does not constitute investment advice.